**Research Article** 



## Asian Journal of Research in Chemistry and Pharmaceutical Sciences

Journal home page: www.ajrcps.com



### MICROWAVE ASSISTED SYNTHESIS AND ANTIBACTERIAL STUDIES OF OXADIAZOLE SUBSTITUTED PYRIMIDINE COMPOUNDS

#### R. Karthic<sup>\*1</sup>, K. Subramani<sup>1</sup>, B. Andrews<sup>2</sup>

<sup>1\*</sup>Department of Chemistry, Islamiah College, Vaniyambadi, (Affiliated to Thiruvalluvar University) Vellore, Tamil Nadu, India.

<sup>2</sup>Department of Chemistry, Priyadarshini Engineering College, Vaniyambadi, (Affiliated to Anna University) Chennai, Tamil Nadu, India.

#### ABSTRACT

A series of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-3, 4-dihydro-6-methyl-4-phenylpyrimidin-2(1*H*)-one derivatives have been synthesized, by changing various substituted benzaldehyde. Simple synthetic methods of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-3, 4-dihydro-6-methyl-4-phenylpyrimidin-2(1*H*)-one (3a-e) are described. Compound 1 is converted to hydrazine carbothiamide2 by reacting compound 1 with thiosemicarbazide in catalytic amount of acetone is irradiated with help of domestic microwave oven (200W) for 2 minutes. Compound 2 is an intermediate for the final compounds. The compound 2 is converted to corresponding oxadiazole3 by treatment with NaOH follow by KI. Structural elucidation is accomplished by IR, <sup>1</sup>H and <sup>13</sup>CNMR, Elemental analysis and GC-Mass spectral data of the synthesized compounds. Few of these Pyrimidine derivatives have been evaluated for their possible antibacterial activity. Most of the tested compounds show significant antibacterial activity.

#### **KEYWORDS**

Pyrimidine, Oxadiazole, Carbothiamide, Antibacterial activity and Microwave.

#### Author for Correspondence:

Karthic R, Department of Chemistry, Islamiah College, Vaniyambadi, Vellore, Tamil Nadu, India.

Email: karthicrm@gmail.com

Available online: www.uptodateresearchpublication.com

#### INTRODUCTON

Pyrimidine derivatives and antimicrobial agent<sup>1</sup> were found to be associated with variety of biological activities such as insecticidal. antimicrobial, antiviral etc., pyrimidine derivatives<sup>2-</sup> <sup>8</sup> with powerful C-C bond formation have broad applications over the preparation of diverse aminoalkyl derivatives. It involves the condensation of compound with the ability of supplying one or more active hydrogen atom to aldehyde and primary or secondary amine. Mannich bases are physiologically reactive because of the molecule January – March 73

soluble in aqueous solvent when it is transformed into ammonium salt. Medicinal uses of several Mannich bases have been reviewed by Tromontini and Angiolini<sup>9</sup>. Besides this, considerable work has been reported on synthesis and pharmacological activities of various Mannich bases for antiviral, analogies, antispasmodic, anesthetic and antimalarial as well as intermediates in drug synthesis. Antiviral properties of certain urea and thiourea derivatives have been reported, in which the antiviral effect is attributed due to the presence of an intact NH-(C=S)-NH and NH-(C=O)-NH grouping<sup>10</sup>. In this direction the synthesis and pharmacological study of Mannich bases of 3-and 5-mercapto derivatives of 1, 3, 4-oxadiazole have literature<sup>11-16</sup>. reported in been Several, pyrimidines. fused heterocyclic pyrimidine derivatives and dihydropyrimidones are known for their biological activity such as antiviral, antitumor, antimicrobial fungicide, algaecide and as antibiotics 17-26 Moreover, the presences of different functional groups show their great synthetic potential. In continuation of this work, herein is reported that the synthesis and in vitro study of antibacterial activity of heterocyclic N-Mannich 5-(5-amino-1,3,4-oxadiazol-2yl)-3,4bases of dihydro-6-methyl-4-phenylpyrimidin-2(1H)-one

against Streptococcus faecalis (Gram (3a-e) +ve), Bacillus sps (Gram +ve) and Escherichia coli (Gram -ve)and Ciprofloxacinis used as standard For this purpose, heterocyclic precursors drug. DHPMs (1a-e) are synthesized by microwave irradiation of aromatic aldehydes, ethylacetoacetate according and thiourea to the literature procedure<sup>27,28</sup> and these DHPMs are used to synthesis compounds (2a-e) and characterized by using elemental analysis, mass spectra, <sup>1</sup>H and <sup>13</sup>CNMR spectral studies.

#### Experimental section

Melting points are determined using open capillary method and are uncorrected. The compounds are checked for homogeneity by TLC on silica gel-G. The FT-IR Thermo Nicolet Avatar 370 spectrophotometer is used to record IR spectra using KBr disc method. The <sup>1</sup>H and <sup>13</sup>CNMR are recorded on Bruker Avance-III 400MHz FTNMR

Available online: www.uptodateresearchpublication.com

spectrometer using DMSO- $d_6$  and mass spectrums are recorded on Joel GC-mate spectrometer. Elemental analysis was recorded on Elemental Vario EL-III instrument. All compounds given satisfactory micro analytical results. Pyrimidine (1) is prepared by reported method<sup>27</sup>.

#### **RESULTS AND DISCUSSION**

Compounds (3a-e) were synthesized according to the scheme 1 and 2. The compound 3a is prepared by reacting hydrazine carbothioamide compound 2 а with NaOH follow by KI. Hydrazine carbothioamide compound 2a is synthesized by reacting pyrimidine ethyl ester 1 with thiosemicarbazide is irradiated in a domestic microwave oven (200W) for 2 minutes<sup>29</sup> and cooled to obtain the product which is recrystallized from ethanol.

The pyrimidine ethyl ester compound 1a prepared by a mixture of aromatic aldehyde (0.01mol), ethylacetoacetate (0.01mol) and urea (0.01mol) is mixed thoroughly with 0.15 mole of tin (II) chloride as catalyst in a conical flask. The content of the flask is irradiated (400W) in a domestic microwave oven for 6 minutes. The completion of the reaction is monitored by TLC. The synthesized compounds are confirmed by IR, <sup>1</sup>H and <sup>13</sup>C-NMR, GC-MS and CHN analysis. Formation of compound 2a is confirmed by the N-H stretching peaks at 3365, 3241 cm<sup>-1</sup> and 3116 cm<sup>-1</sup> and C=O stretching peaks at 1724 cm<sup>-1</sup> in IR and singlet at  $\delta$ 6.50 for NH<sub>2</sub> group in <sup>1</sup>HNMR spectra.

Treatment of compound 2a with NaOH follow by KI, furnished 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-3, 4-dihydro-6-methyl-4-phenylpyrimidin-2(1*H*)-one

(3a-e). The structure of 3a is elucidated on the basis of C-O-C linkage in the oxadiazole ring, which causes a sharp absorption band at 1020 cm<sup>-1</sup> in its IR spectrum. <sup>1</sup>HNMR spectrum showed a singlet at  $\delta$  3.98 due to NH<sub>2</sub> functionality confirmations of the structure 3a.

The IR and <sup>1</sup>HNMR spectral data revealed carbonyl absorption band at 1699 cm<sup>-1</sup> of NH-CO-NH group, N-N stretching band at1089 cm<sup>-1</sup> aliphatic C-H and aromatic C-H stretching at 2978 cm<sup>-1</sup> and 3033cm<sup>-1</sup> for pyrimidine moiety 3. Mass spectrum also January – March 74

supports the proposed structure by viewing molecular ion peak atm/z 271 M<sup>+</sup>.

#### **General Procedure**

#### Synthesis of 5-(hydrazine carbothioamide)-6methyl-4-phenyl-3, 4-dihydropyrimidine -2(1*H*)-one (2a)

An equimolar mixture of compound1 (0.01mol) and thiosemicarbazide (0.01mol) with catalytic amount of acetone is irradiated in a domestic microwave oven (200W) for 2 minutes and cooled to obtain the product which is recrystallized from ethanol. The compounds prepared in this manner (2a-e) are listed in Table1. Melting point of the compound is 140°C yield 85%. <sup>1</sup>HNMR (400MHz, DMSO- $d_6$ )  $\delta$  2.251 (s, 3H), 5.152 (d, J = 3.2Hz,1H), 6.501 (s, 2H), 7.213–7.336 (m, 5H), 7.702 (d, J= 2.8Hz, 1H), 8.175 (d, J= 6.4Hz, 2H,), 9.149 (s, 1H); <sup>13</sup>CNMR (400MHz, DMSO-*d*<sub>6</sub>) δ 17.72, 59.17, 99.33, 126.21, 127.23, 128.34, 148.25, 151.71, 152.16, 165.33, 178.40; FT-IR (KBr) 3365, 3241, 3116 (NH), 3079 (Ar-H), 2978 (CH), 1724 (C=O), 1385 (C-N), 1219 (C=S), 1089 (N-N) cm<sup>-1</sup>; GCMS: m/z 305 [M<sup>+</sup>]. Elemental Anal. (%) (C<sub>13</sub>H<sub>15</sub>O<sub>2</sub>N<sub>5</sub>S), Calculated; C 51.17, H 4.94, N 22.50, S 10.47. Found; C 51.10, H 4.85, N 22.24, S 10.94.

# General procedure for Synthesis of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-3, 4-dihydro-6-methyl-4-phenylpyrimidin-2(1*H*)-one (3a)

General procedure for Synthesis of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-3, 4-dihydro-6-methyl-4phenylpyrimidin-2(1H)-one, (3a), for the compounds (3a-e) are listed in Table No.2, carbothioamide2 (0.01 mol) is added into 10% NaOH with cooling and shaking. Then Iodine solution in KI is added gradually and shaking until the Iodine color persisted. This reaction mixture is heated continuously for 5hr and it is concentrated the residue, its cooled and poured onto ice cold water. This solution is filtered and acidified with 10% HCl to isolate the product. It is filtered and washed with cold water and little amount of CS2is added. The product is purified by recrystallization from alcohol. m.p.175-177°C, Yield 78%. <sup>1</sup>HNMR (DMSO-d<sub>6</sub>): δ 2.264 (s,3H,CH<sub>3</sub>), 3.987 (s, 2H, NH<sub>2</sub>), 5.167 (J=3.2Hz, d, 1H, CH), 7.245-7.347 (m, 5H, Ar-H), 7.717 (J=1.6Hz, d, 1H, NH), 9.165

Available online: www.uptodateresearchpublication.com

(s, 1H, NH); <sup>13</sup>CNMR (DMSO-*d*<sub>6</sub>): δ17.73, 59.14, 99.29. 126.22, 127.21, 128.33, 142.03, 144.83, 148.28, 152.14, 165.31; FT-IR (KBr): 3375, 3242, 3115(NH), 3033 (Ar-H), 2978(CH), 1699(C=O), 1598 (C=N), 1340 (C-N), 1089 (N-N), 1020cm<sup>-1</sup>(C-O); GCMS: *m*/*z* [271 M<sup>+</sup>]. Synthesis of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-4-(4-chlorophenyl)-3, 4-dihydro-6-methylpyrimidin-2(1*H*)-one (3b): <sup>1</sup>HNMR (DMSO- $d_6$ ):  $\delta 2.255$  (s, 3H, CH<sub>3</sub>), 3.997 (s,2H, NH<sub>2</sub>), 5.152 (J=3.6Hz, d,1H, CH), 7.243-7.299 (m, 4H, Ar-H), 7.735 (J=2.8Hz, d, 1H, NH), 9.207 (s, 1H, NH); <sup>13</sup>CNMR (DMSO-*d*<sub>6</sub>):  $\delta$ 17.76, 59.21, 98.85, 128.15, 128.34, 131.77, 143.76, 148.65, 151.94, 165.17; FT-IR (KBr): 3376, 3244, 3116(NH), 2980 (Ar-H), 2956 (CH), 1723 (C=O), 1534 (C=N), 1367 (C-N), 1170 (C-O),  $1087 \text{ cm}^{-1}$ (N-N); GCMS: m/z [305 M<sup>+</sup>]. Synthesis of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-3, 4-dihydro-4-(4-hydroxyphenyl)-6-methylpyrimidin-2(1H)-one (3c):<sup>1</sup>HNMR(DMSO-d<sub>6</sub>):  $\delta 2.286$  (s, 3H, CH<sub>3</sub>), 4.046 (s, 2H, NH<sub>2</sub>), 5.100 (J=3.6Hz, d, 1H, CH), 6.765-7.793 (q, 2H, Ar-H), 7.013-7.033 (q, 2H, Ar-H), 9.187 (J=1.2Hz, d, 1H, NH), 9.347 (s, 1H, NH), 10.296 (s, 1H, OH); <sup>13</sup>CNMR (DMSOd<sub>6</sub>): δ17.69, 59.07, 99.78, 114.96, 127.36, 135.41, 136.72, 148.10, 151.98, 152.17, 165.25; FT-IR(KBr): 3291 (OH), 3218,3121 (NH), 3021 (Ar-H), 2981 (CH), 1692 (C=O), 1514 (C=N), 1316 (C-N), 1101 (N-N), 1023cm<sup>-1</sup> (C-O); GCMS: *m/z* [287  $M^{+}$ ].

Synthesis of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-4phenyl)-3, (4-(dimethylamino) 4-dihydro-6methylpyrimidin-2(1H)-one (3d):<sup>1</sup>HNMR (DMSO*d*<sub>6</sub>): δ2.227 (s, 3H, CH<sub>3</sub>), 2.848 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>), 3.986 (s, 2H, NH<sub>2</sub>), 5.038 (J=4.4Hz, d, 1H, CH), 6.658 (J=8.8Hz, d, 2H, Ar-H), 7.022-7.058 (m, 2H, Ar-H), 7.539 (J=2.8Hz, d, 1H, NH), 9.041(s, 1H, NH); <sup>13</sup>CNMR (DMSO-*d*<sub>6</sub>): δ17.68, 53.28, 59.05, 99.89, 112.29, 126.86, 132.76, 134.25, 147.50, 149.65, 152.25, 165.46. FT-IR (KBr): 3380, 3245, 3114 (NH), 2953 (Ar-H), 2811 (CH), 1719 (C=O), 1560 (C=N), 1384 (C-N), 1091 (N-N), 1025cm<sup>-1</sup>(C-O); GCMS: m/z [314 M<sup>+</sup>]. Synthesis of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-3, 4-dihydro-6-methyl-4-(3nitrophenyl) pyrimidin-2(1*H*)-one (3e): <sup>1</sup>HNMR (DMSO-d<sub>6</sub>):  $\delta 2.283$  (s, 3H, CH<sub>3</sub>), 4.039 (s, 2H, January – March 75

NH<sub>2</sub>), 5.314 (*J*=3.6Hz,d, 1H, CH), 7.699-8.142 (m, 4H, Ar-H), 8.722 (*J*=10.4Hz, d, 1H, NH), 9.310 (s, 1H, NH);  $^{13}$ CNMR (DMSO-*d*<sub>6</sub>):  $\delta$ 17.81, 59.35, 98.35, 122.26, 130.10, 130.14, 132.94, 146.96, 147.70, 148.30, 149.35, 151.77, 165.02; FT-IR (KBr): 3566, 3440, 3335 (NH), 3090 (Ar-H), 2966 (CH), 1707 (C=O), 1526 (C=N), 1316 (C-N), 1088 (N-N), 1007cm<sup>-1</sup> (C-O); GCMS: *m/z* [316 M<sup>+</sup>].

#### Antibacterial studies

Among the newly synthesized pyrimidine derivatives are screened for their antibacterial activity *in vitro* against the species of *Streptococcus faecalis, Bacillus sps and Escherichia coli*, using agar well disk diffusion method. The test compounds are dissolved in DMSO to get a solution of  $10\mu$ g/mL concentration. The inhibition zones are measured in millimeters at the end of an incubation period of 18hrs at 37<sup>o</sup>C. Ciprofloxacin is used as a standard and the results are shown in Table No.3. Most of the tested compounds show moderate to good inhibition.

| Compd. | Mol. Formula                | R                             | R <sub>1</sub>  | X | Mol.Wt | Yield | m.p               | Calcd. /Found (%) |       |      |        |
|--------|-----------------------------|-------------------------------|-----------------|---|--------|-------|-------------------|-------------------|-------|------|--------|
| Compa. | wor. For mula               | N                             | <b>N</b> 1      | Λ |        | (%)   | ( <sup>0</sup> C) | С                 | Ν     | Н    | S      |
| 2a     | $C_{13}H_{15}O_2N_5S$       | Н                             | Н               | 0 | 305    | 85    | 140               | 51.17             | 22.50 | 4.94 | 10.47  |
| Za     | $C_{13}I_{15}O_{2}I_{5}S$   | 11                            | 11              | 0 | 505    | 65    |                   | (51.94            | 22.24 | 4.85 | 10.94) |
| 2b     | $C_{13}H_{14}O_2N_5SCl$     | Cl                            | Н               | 0 | 339    | 70    | 145               | 46.05             | 20.65 | 4.15 | 9.42   |
| 20     | $C_{13}I_{14}O_{2}I_{5}SCI$ | CI                            | 11              | 0 | 559    | 70    |                   | (46.30            | 20.94 | 4.60 | 9.49)  |
| 2c     | C. H. O. N.S.               | OH                            | Н               | 0 | 321    | 83    | 160               | 48.62             | 21.18 | 4.70 | 9.95   |
| 20     | $C_{13}H_{15}O_3N_5S$       | ОП                            | п               | 0 | 521    | 05    |                   | (48.75            | 21.19 | 4.32 | 9.36)  |
| 2d     | CULUCONS                    | $\mathbf{N}(\mathbf{CH}_{i})$ | Н               | 0 | 348    | 70    | 78 170            | 52.35             | 24.42 | 5.84 | 9.28   |
| 20     | $C_{15}H_{20}O_2N_6S$       | $N(CH_3)_2$                   | п               | 0 | 540    | /0    |                   | (52.79            | 24.77 | 5.83 | 9.85)  |
| 20     |                             | Н                             | NO <sub>2</sub> | 0 | 350    | 81    | 132               | 44.60             | 24.00 | 4.02 | 9.13   |
| 2e     | $C_{13}H_{14}O_4N_6S$       | п                             |                 |   |        |       |                   | (44.06            | 24.07 | 4.43 | 9.22)  |


 Table No.1: Physical and analytical data of compounds (2a-e)

| Table No.2: Physical and analytical data of compounds (3a-e) |                        |                                  |                 |   |        |       |                   |                    |       |      |       |
|--|------------------------|----------------------------------|-----------------|---|--------|-------|-------------------|--------------------|-------|------|-------|
| Comnd  | Mol. Formula           | R                                | $\mathbf{R}_1$  | X | Mol.Wt | Yield | m.p               | Calcld. /Found (%) |       | )    |       |
| Compd  | NIOI. FOFILIUIA        | Л                                | <b>K</b> 1      | Λ |        | (%)   | ( <sup>0</sup> C) | С                  | Ν     | Н    | S     |
| 3a   | $C_{13}H_{13}O_2N_5$   | Н                                | Н               | 0 | 271    | 78    | 175-              | 57.52              | 25.80 | 4.07 | 0.00  |
|  |                        |                                  |                 |   |        |       | 177               | (57.59             | 25.82 | 4.83 | 0.00) |
| 3b   | $C_{13}H_{12}O_2N_5Cl$ | Cl                               | Н               | 0 | 305    | 72    | 197-              | 51.28              | 22.76 | 3.64 | 0.00  |
|  |                        |                                  |                 |   |        |       | 199               | (51.07             | 22.95 | 3.96 | 0.00) |
| 3c   | $C_{13}H_{13}O_3N_5$   | ОН                               | Н               | 0 | 287    | 85    | 124-              | 54.10              | 24.95 | 4.57 | 0.00  |
|  |                        |                                  |                 |   |        |       | 126               | (54.38             | 24.38 | 4.56 | 0.00) |
| 3d   | $C_{15}H_{18}O_2N_6$   | N(CH <sub>3</sub> ) <sub>2</sub> | Н               | 0 | 314    | 88    | 204-              | 57.51              | 26.71 | 5.25 | 0.00  |
|  |                        |                                  |                 |   |        |       | 206               | (57.34             | 26.75 | 5.77 | 0.00) |
| 3e   | $C_{13}H_{12}O_4N_6$   | Н                                | NO <sub>2</sub> | 0 | 316    | 69    | 135-              | 49.89              | 26.46 | 3.86 | 0.00  |
|  |                        |                                  |                 |   |        |       | 137               | (49.39             | 26.82 | 3.82 | 0.00) |


Karthic R. et al. /Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 7(1), 2019, 73-79.

| S.No | Compound | Streptococcus faecalis(+ve) | <b>Bacillus sps (+ve)</b> | Escherichia coli (-ve) |  |  |  |  |  |
|------|----------|-----------------------------|---------------------------|------------------------|--|--|--|--|--|
| 1    | Control  | 0                           | 0                         | 0                      |  |  |  |  |  |
| 2    | 3a       | 7                           | 8                         | -                      |  |  |  |  |  |
| 3    | 3b       | 9                           | 12                        | -                      |  |  |  |  |  |
| 4    | 3c       | 12                          | 6                         | 9                      |  |  |  |  |  |
| 5    | 3d       | 7                           | 9                         | -                      |  |  |  |  |  |
| 6    | 3e       | 9                           | 4                         | 6                      |  |  |  |  |  |


Table No.3: Antibacterial activities of compounds (3a-e)



Scheme No.1: Synthesis of 5-(hydrazine carbothioamide)-6-methyl-4-phenyl-3, 4-dihydropyrimidin-2(1*H*)-one (2a-e)



Scheme No.2: Synthesis of 5-(5-amino-1, 3, 4-oxadiazol-2-yl)-3, 4-dihydro-6-methyl 4-Phenylpyrimidin-2(1*H*)-one (3a-e)



#### CONCLUSION

The investigation of antibacterial screening data reveals that, all the tested compounds show moderate to good inhibition at  $10\mu$ g/ml concentration. Especially, the compound 3b and 3c shows very good activity than the others and also the compound3e show moderate inhibition against all the three species.

#### ACKNOWLEDGEMENT

The authors are thankful to Principal and Research Department of chemistry, Islamiah College, Vaniyambadi, Vellore district, Tamilnadu for constant encouragement and providing necessary facilities.

#### **CONFLICT OF INTEREST**

We declare that we have no conflict of interest.

#### BIBLIOGRAPHY

- 1. Kape Oliver C. 100 years of the biginelli dihydropyrimidine synthesis, *Tetrahedron*, 49(32), 1993, 6937-6963.
- 2. Ugi L, Domling A, Horl W. Multicomponent reactions in organic chemistry, *Endeavour*, 18(3), 1998, 115-122.
- 3. Kape Oliver C. Biologically active dihydropyrimidones of the Biginelli-type-a literature survey, *Eur. J. Med. Chem*, 35(12), 2000, 1043-1052.
- Mannich C and Lammering D. Über die Synthese von β-Keto-basen aus fett-aromatischen Ketonen, Formaldehyd und sekundären Aminen, *Chem. Ber*, 55(10), 1922, 3510-3526.
- 5. Manjula A, Rao B V and Neelakantam P. An inexpensive protocol for Biginelli reaction: Synthesis of pyrimidine compound, *Synth. Commun*, 34(14), 2011, 2665-2671.
- Andrew J, Hong Wang A, Sakwa A. Synthesis and Suzuki-Miyaura reaction: Synthesis of dihydropyrimidine-2(1H)-one, *Tetrahedron Lett*, 51(39), 2010, 5103-5105.

Available online: www.uptodateresearchpublication.com

- 7. Garima P, Vishnu S, Lal Dhar, Yadav. Biginelli reaction: Starting directly from alcohol, *Tetrahedron Let*, 51(49), 2010, 6436-6438.
- 8. Sergey V, Ryabukhin Andrey S, Plaskon, Ostapchuk, Grygorenko Oleg V, Shishkin Andrey A, Tolmachev. Acyl pyruvates as synthesis: Biginelli reaction, *Tetrahedron lett*, 51(32), 2010, 4229-4232.
- 9. Tramontini M and Angiolini L. Mannich Bases; Chemistry and uses, (CRC Press, Boca Raton), 1994, 304.
- 10. Zang H, Vrang L, Bacbro K, Lind P and Oberg B. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127, *Antiviral Res*, 28(4), 1995, 331-342.
- 11. Hai-Ming Guo, Yan-Yan W U and Gui-Rong Qu. Synthesis of Acyclic Nucleosides with a Chiral Amino Side Chain by the Mitsunobu Coupling Reaction, J. Org. Chem, 75(11), 2010, 3863-3866.
- Hellmann H and Loschman I, Über N-Mannich-Basen I. Mitteil.: Mannich-Basen von cyclischen Amiden und Aminen, *Chem. Ber*, 87(11), 1954, 1684-1686.
- 13. Moore M B and Rapela R T. N-Alkamine Substituted Phthalimides, *J. Am. Chem. Soc*, 68(8), 1946, 1657-1660.
- 14. Atkinson R O, J. Chem. Soc, 1954, 1329-1332.
- 15. Varma R S. Aminomethylation reactions of nitrogen and sulfur five membered heterocyclic compounds, *J. Indian Chem. Soc*, 81(8), 2004, 627-629.
- 16. Narwade S K, Dalvi N R and Karale B.K. Conventional and ultrasound mediated synthesis of some thiadiazoles, triazoles and oxadiazoles, *Indian J. Chem*, 45B, 2006, 2776-2780.
- 17. Kidwai M, Venkataramanan R and Dave B. Potassium carbonate, a support for the green

January – March

synthesis of azoles and diazines, *J. Heter. Chem*, 39(5), 2002, 1045-1047.

- Ross N A and Burtsch R A. Sonochemical reformatsky reactions of α-bromoesters with sym- (keto) dibenzo-16-crown-5, *J.Heter. Chem*, 38(6), 2001, 1255-1259.
- 19. Singh V, Sapehiyia V and Kad G L. Synthesis, 7(2), 2003, 198-201.
- 20. Swati Ojha, Neelam Dhakar and Talesara. Synthesis and characterization of some alkoxyphthalimide derivatives of benzotriazolylthiadiazoles and benzotriazolylthiazolidinones, *Indian J. Chem*, 46B(5), 2007, 860-865.
- 21. Z. XiajuanandJ. Guiyu, Synthesis of pyridazinonesubstituted 1, 3, 4-thiadiazoles, -1, 3, 4-oxadiazoles and -1, 2, 4-triazoles, *J. Heter. Chem*, 38(4), 2001, 993-995.
- 22. Jagadhani S G, More M S and Karale B K. Indian J.Heter. Chem, 15, 2006, 335-338.
- Ravindra K C and Vagdevi M H. Synthesis of 4-((benzo [d] isoxazol-3-yl) methyl)-Nphenyl-1, 3, 4-thiadiazol-2-amines and 5-(benzo [d] isoxazol-3-yl) methyl)-4-phenyl-4H-1, 2, 4-triazole-3-thiols, *Indian J.Heter. Chem*, 15(4), 2006, 335-336.
- 24. Bhavsar A M, Shah M D and Desai N C. Synthesis and QSAR Studies of thiosemicarbazides, 1, 2, 4-triazoles, 1, 3, 4thiadiazoles and 1, 3, 4-oxadiazoles as potential antibacterial agents, *Indian J. Chem*, 47B(4), 2008, 579-589.
- 25. Andrews B and Mansur Ahmed. Novel synthesis and characterization of some pyrimidine derivatives of oxadiazoles, triazoles and thiadiazoles, *Asian J. Chem*, 25(4), 2013, 2070-2072.
- 26. Andrews B and Mansur Ahmed, Synthesis and Characterization of Pyrimidine Derivatives of 1, 3, 4-Oxadiazole and 1, 3, 4-Thiadiazole, *J. Chem. Pharma. Research*, 4(8), 2012, 3920-3923.

- 27. Dipak K, Roy and Manobjyoti Bordoloi. Synthesis of some substituted 2-oxo- 1, 2, 3, 4-tetrahydropyrimidines (3, 4-dihydropyrimidin-2(1*H*)-ones) and 2-thioxo-1, 2, 3, 4-tetrahydropyrimidines, catalyzed by tin (II) chloride dihy drate and tin (II) iodide under microwave irradiation, *Indian J. Chem*, 45B(4), 2006, 1067-1071.
- 28. Niharika I, Sandip S, Kshirsagar, Hemlata M, Chaudhari S, Microwave assisted synthesis of 4 substituted 1, 2, 3, 4 tetra hydro pyrimidine derivatives, *Int.J.Pharm and Pharma. Sci*, 3(1), 2011, 109-111.
- 29. Moayed S, Al-Gwady. Synthesis of 2-Amino-5-Substituted-1, 3, 4-Thiadiazoles (ATDA) and Their Derivatives Using Conventional and Microwave Techniques, J. *Raf. Sci*, 20(1), 2009, 1-7.

**Please cite this article in press as:** Karthic R *et al.* Microwave assisted synthesis and antibacterial studies of oxadiazole substituted pyrimidine compounds, *Asian Journal of Research in Chemistry and Pharmaceutical Sciences*, 7(1), 2019, 73-79.